Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-128800 dose-finding study in relapsing-remitting multiple sclerosis
NL-OMON35354Phase 2Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2010
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ponesimod in multiple sclerosis (MS), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Cumulative number of new gadolinium-enhancing lesions. Started Apr 2010; status: active, not recruiting.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON35354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35354.